Georg Karpel-Massler (G Karpel-Massler)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Venues

British journal of cancer

Neurochemical research

Cancers

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer 130 (8) (2024)
Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer 130 (8) (2024)
Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer 130 (8) (2024)
Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer (2024)
Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer 130 (8) (2024)
Qiyu Cao, Annika Hajosch, Richard Eric Kast, Christopher Loehmann, Michal Hlavac, Pamela Fischer-Posovszky, Hannah Strobel, Mike-Andrew Westhoff, Markus D Siegelin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British journal of cancer 130 (8) (2024)
Trang Thi Thu Nguyen, Enyuan Shang, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma. Cells 11 (19) (2022)
Trang Thi Thu Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V Prabhu, Joshua E Allen, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D Siegelin
Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (9) (2022)
Marc-Eric Halatsch, Annika Dwucet, Carl Julius Schmidt, Julius Mühlnickel, Tim Heiland, Katharina Zeiler, Markus D Siegelin, Richard Eric Kast, Georg Karpel-Massler
In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Carolin Golla, Mayas Bilal, Annika Dwucet, Nicolas Bader, Jenson Anthonymuthu, Tim Heiland, Maximilian Pruss, Mike-Andrew Westhoff, Markus David Siegelin, Felix Capanni, Christian Rainer Wirtz, Richard Eric Kast, Marc-Eric Halatsch, Georg Karpel-Massler
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma. Cancers 13 (16) (2021)
Michal Hlavac, Annika Dwucet, Richard Eric Kast, Jens Engelke, Mike-Andrew Westhoff, Markus D Siegelin, Klaus-Michael Debatin, Christian Rainer Wirtz, Marc-Eric Halatsch, Georg Karpel-Massler
Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. Cellular oncology (Dordrecht) 42 (3) (2019)
Marc-Eric Halatsch, Richard Eric Kast, Annika Dwucet, Michal Hlavac, Tim Heiland, Mike-Andrew Westhoff, Klaus-Michael Debatin, Christian Rainer Wirtz, Markus David Siegelin, Georg Karpel-Massler
Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. British journal of pharmacology 176 (18) (2019)
Georg Karpel-Massler, M-A Westhoff, R E Kast, A Dwucet, S Karpel-Massler, L Nonnenmacher, M D Siegelin, C R Wirtz, K-M Debatin, M-E Halatsch
Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro. Neurochemical research 42 (5) (2017)
Georg Karpel-Massler, Richard E Kast, Markus D Siegelin, Annika Dwucet, Elisabeth Schneider, Mike-Andrew Westhoff, Christian Rainer Wirtz, Xiao Yun Chen, Marc-Eric Halatsch, Carsten Bolm
Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification. Neurochemical research 42 (12) (2017)

Georg Karpel-Massler.css-eqlu8i{font-size:small;padding-left:4px;} (G Karpel-Massler)

Publication Activity (10 Years)

Top Topics

Top Venues

Georg Karpel-Massler (G Karpel-Massler)